Clinical Trial: Lemborexant Efficacy and Safety in Liver Cirrhosis-Randomized, Double-Blind, Crossover Clinical Trial [0.03%]
仑博雷克桑治疗肝硬化患者的有效性和安全性-随机双盲交叉临床试验
Rino Alvani Gani,Pitt Akbar,Irsan Hasan et al.
Rino Alvani Gani et al.
Background and aim: No pharmacologic treatment has yet been approved for sleep disturbances in cirrhosis, a high-risk group with substantial prevalence and clinical consequences. Lemborexant has shown efficacy for insomni...
C Mel Wilcox
C Mel Wilcox
Letter: Severity-Informed Enrichment for Recurrent Acute Pancreatitis Trials [0.03%]
信件：复发性急性胰腺炎试验的严重程度信息丰富度
Fangrong Jiang,Ting Shen
Fangrong Jiang
Editorial: Mind the Gap-Peripheral Immune Signatures of HBV Cirrhosis in an Underserved Population [0.03%]
编者按：关注缺口——未被充分服务的人群中HBV肝硬化外周免疫特征
Martin Feuerherd
Martin Feuerherd
Editorial: Fatigue in Disorders of Gut-Brain Interaction-An Important Symptom to Recognise [0.03%]
肠道脑交互障碍所致的疲劳症状不容忽视
Joost P Algera,Tom van Gils
Joost P Algera
Editorial: Non-Selective Beta-Blockers in Decompensated Cirrhosis-More Friends Than Foes [0.03%]
编者按：失代偿期肝硬化患者使用非选择性β受体阻滞剂益处多于风险
Roberta Gagliardi,Annalisa Berzigotti
Roberta Gagliardi